Drug Trial Radar · NCT07340619
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Sep 18, 2026
Primary completion
Nov 18, 2028
Study completion Nov 18, 2029
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body). Among the different types of breast cancer, hormone-sensitive cancers that do not overexpress the HER2 protein (HR+/HER2-) are the most common. For patients with this type of cancer, an endocrine treatment such as aromatase inhibitors, tamoxifen or fulvestrant, is often used and may be combined with drugs called CDK4/6 inhibitors, which help improve survival rate. However, when the cancer becomes resistant to these treatments, treatment strategies are more limited A new drug, prifetrastat (PF-07248144), which targets KAT6 proteins, which play a role in the growth of cancer cells, has shown promising results. Indeed, associated with fulvestrant, it allowed to fight against cancer in some patients who had already received many treatments. The UNLOCK-EPIBREAST study aims to investigate whether the combination of prifetrastat plus fulvestrant could offer a new therapeutic option for people with HR+/HER2- metastatic breast cancer who have already received endocrine therapy plus CDK4/6 inhibitors.
Conditions
- Metastatic (Stage IV) Melanoma
Interventions
prifetrastat monotherapy for 15 days then combination with fulvestrantDrug
Patients will receive prifetrastat 5mg QD monotherapy for 2 weeks and then combination of prifetrastat 5mg QD plus fulvestrant 500-mg intramuscular injection on day 15 cycle 1, on day 1 and day 15 of cycle 2 and then on day 15 of subsequent 28-day (±3 days) cycles.
prifetrastat in combination with fulvestrantDrug
Patients will receive combination prifetrastat 5mg QD plus fulvestrant 500-mg intramuscular injection on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day (±3 days) cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective of the study is to assess the effect of prifetrastat with fulvestrant on ctDNA-based mutation burden among patients with HR+/HER2- mBC.Time frame: From first treatment administration to disease progression or death, up to 5 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Centre Antoine Lacassagne
Nice, France
Institut Curie
Paris, France
Centre Eugene Marquis
Rennes, France
Institut de Cancerologie de L'Ouest
Saint-Herblain, France
Oncopole Claudius Regaud
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.